Both omega-3, placebo help with aromatase inhibitor-induced pain
Dawn L. Hershman, M.D., from the Columbia University Medical Center in New York City, and colleagues randomized 249 women with early-stage breast cancer receiving an AI who had a worst joint pain/stiffness score of ≥5 of 10 using the Brief Pain Inventory-Short Form (BPI-SF) to receive O3-FAs (122 patients) or placebo (127 patients) for 24 weeks. Patients completed quality-of-life and additional pain and stiffness assessments at baseline and at weeks six, 12, and 24.
The researchers found that the mean observed BPI-SF score decreased by 1.74 and 2.22 points at 12 and 24 weeks, respectively, with O3-FAs, and by 1.49 and 1.81 points, respectively, with placebo, compared with baseline. Twelve-week BPI-SF scores did not differ by arm (P = 0.58) after adjustment for baseline score, osteoarthritis, and taxane use. In patients receiving O3-FA treatment, triglyceride levels decreased, while they remained stable for patients receiving placebo (P = 0.01).
"We found no evidence that O3-FAs improved joint pain or stiffness associated with AIs any more than placebo; however, we did find a large reduction in symptoms in both the treatment and placebo groups," the authors write.
Several authors disclosed financial ties to the pharmaceutical and biopharmaceutical industries.
Full Text (subscription or payment may be required)
Copyright © 2015 HealthDay. All rights reserved.